Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

F-star Therapeutics, Inc. (FSTX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
6.50-0.07 (-1.07%)
At close: 04:00PM EDT
6.50 0.00 (0.00%)
After hours: 04:01PM EDT
Advertisement
Full screen
Loading interactive chart...
  • GlobeNewswire

    F-star Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights

    Previously announced agreement for F-star Therapeutics to be acquired by invoX Pharma; transaction expected to close in the second half of 2022 License Agreement with Takeda to Develop and Commercialize a Novel Next-Generation Immuno-Oncology Bispecific Antibody TherapeuticFS118 Cleared the Futility Hurdle for the Initial Stage of the Head and Neck Acquired Resistance Cancer Trial Initiation of Combination Dosing with FS120 and KEYTRUDA® in Patients with Advanced Cancers under Supply Agreement w

  • GlobeNewswire

    F-star Therapeutics Announces a License Agreement with Takeda for a Novel Next-Generation Immuno-oncology Bispecific Antibody

    CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., July 20, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star”), operating through its subsidiary, F-star Therapeutics Ltd., a clinical-stage biopharmaceutical company pioneering bispecifics in immunotherapy so more people with cancer can live longer and improved lives, today announced that it has entered into a license agreement with Takeda. Under the terms of the agreement, F-star will grant Takeda a worldwide, exclusive roy

  • Simply Wall St.

    How Much Of F-star Therapeutics, Inc. (NASDAQ:FSTX) Do Institutions Own?

    If you want to know who really controls F-star Therapeutics, Inc. ( NASDAQ:FSTX ), then you'll have to look at the...

Advertisement
Advertisement